All In MedTech

Device Trial Radar · NCT06891729

Plan A Novel Delivery Device Study

Safety and Clinical Validation Study of the Plan A Delivery Lumen Access Device (DLAD)

Last checked: Nov 20, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Mar 15, 2025

Primary completion

Jun 29, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Next Life SciencesNot on our public-company list
Sponsor type
Industry
Collaborators
Southern Star Research
First posted
Mar 24, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and usability of the Delivery Lumen Access Device (DLAD) in accessing the vas deferens in up to 30 healthy males. This is a prospective, non-randomized, open label interventional study.

Conditions

  • Healthy Male Adults Participants
  • Vasectomy

Interventions

  • Delivery Lumen Access DeviceDevice

    Delivery Lumen Access Device use prior to Vasectomy

  • DLADDevice

    Participants will be exposed to the DLAD during their planned vasectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 14 days post vasectomy procedure.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Epworth HealthCare

    Melbourne, Victoria, Australia

  • VasectoPro

    Québec, Quebec/Canada, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.